Search Cancer Clinical Trials

Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
19 results
  • Thyroid Cancer, Lung Cancer, Head and Neck Cancer

17-241          Phase I

A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)

  • Ovarian Cancer, Endometrial Cancer, Esophageal Cancer, Head and Neck Cancer, Lung Cancer

25-622          Phase II

A Phase 1/2 Trial of TER-2013 in Participants with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer, Breast Cancer, Cervical Cancer

24-353          Phase I

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

  • Head and Neck Cancer

24-269          Phase III

A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First-Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS =20) (HexAgon-HN)

  • Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Rectal Cancer, Thymoma, Gastric (Stomach) Cancer, Esophageal Cancer, Colorectal Cancer

23-423          Phase I

A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination with Pembrolizumab in Patients with Select Advanced Cancers

  • Colorectal Cancer, Endometrial Cancer, Gastric (Stomach) Cancer, Head and Neck Cancer, Metastatic/Advanced Cancer, Ovarian Cancer, Breast Cancer, Cervical Cancer

23-618          Phase I

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors

  • Melanoma, Lung Cancer, Liver Cancer, Head and Neck Cancer, Endometrial Cancer, Colorectal Cancer, Bladder Cancer

24-203          Phase I

An Open-Label Study of GV20-0251 in Patients with Advanced and/or Refractory Solid Tumor Malignancies

  • Endometrial Cancer, Head and Neck Cancer, Ovarian Cancer, Breast Cancer

23-044          Phase II

First-in-Human Study of STX-478, a Mutant-Selective PI3Ka Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

  • Melanoma, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Breast Cancer, Bladder Cancer

22-405          Phase II

Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors

Showing 1 - 10 of 19 results